Roohangiz Nashibi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roohangiz Nashibi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Mehdi Parsanahad
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, ajums.ac.ir
2 shared publications - Niloofar Neisi
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 shared publications - Azarakhsh Azaran
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
1 shared publication - Farhad Abolnezhadian
Division of Immunology and Allergy, Department of Pediatrics, Abuzar Children’s Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
1 shared publication Farid Yousefi
Ahvaz JundishapurUniv Med Sci, Sch Med, Dept Infect Dis, Ahvaz, Iran
1 shared publication- Fatemeh Ahmadi
Ahvaz JundishapurUniv Med Sci, Sch Med, Dept Infect Dis, Ahvaz, Iran
1 shared publication
Latest Publications
- Open Access
- 17 August 2025
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 18 (9) , e165380
Elevated miRNA Expression and IL-6 Levels in COVID-19 Patients: Correlations and Implications for Inflammatory Response
Background: The role of microRNAs (miRNAs) in viral diseases is well established. Due to the COVID-19 pandemic, this study analyzed the expression levels of miR200b-3p, miR34b-5p, miR203a-3p, and Let7g-5p in the blood samples of COVID-19 patients, along with the expression level of interleukin-6 (IL-6) as a biomarker. Objectives: The purpose of this study is to investigate the correlation between the expression levels of IL-6 and the mentioned miRNAs. Methods: The study included 60 COVID-19 patients confirmed by an infectious disease specialist and positive real-time PCR tests, hospitalized at Razi Hospital, Ahvaz. The control group consisted of thirty healthy people. COVID-19 disease was verified using oro-nasopharyngeal swab samples, and PBMC samples from patients were used to check the expression level of IL-6. Plasma samples were analyzed for the expression levels of miR200b-3p, miR34b-5p, miR203a-3p, and Let7g-5p. Results: All examined expression factors were markedly elevated in COVID-19 patients in comparison to the control group. Specifically, miR200b-3p (P < 0.00), Let7g-5p (P < 0.003), and miR203a-3p (P < 0.00) exhibited significantly higher levels in the infected group. MiR34b-5p (P < 0.02) also showed an increase, albeit to a lesser extent. Additionally, IL-6 expression was substantially higher in hospitalized patients. Positive correlations, though not statistically significant, were observed between miR200b-5p, miR203a-3p, miR34b-5p, and IL-6 expression. Conversely, a non-significant negative correlation was noted between Let7g and IL-6 in COVID-19 patients. Conclusions: This study establishes a relationship between the elevated expression of specific miRNAs (miR200b-3p, miR34b-5p, miR203a-3p, and Let7g-5p) and IL-6 in COVID-19 patients. The significant upregulation of these miRNAs, alongside increased IL-6 levels, underscores their potential role as biomarkers for COVID-19. These findings suggest that miRNA and IL-6 expression profiles could be instrumental in the diagnosis and management of COVID-19, providing new avenues for therapeutic interventions and improving patient outcomes.
- 17 August 2025
- Published by Brieflands in Jundishapur Journal of Microbiology
- Vol. 18 (9) , e165380
Open AccessElevated miRNA Expression and IL-6 Levels in COVID-19 Patients: Correlations and Implications for Inflammatory Response
Background: The role of microRNAs (miRNAs) in viral diseases is well established. Due to the COVID-19 pandemic, this study analyzed the expression levels of miR200b-3p, miR34b-5p, miR203a-3p, and Let7g-5p in the blood samples of COVID-19 patients, along with the expression level of interleukin-6 (IL-6) as a biomarker. Objectives: The purpose of this study is to investigate the correlation between the expression levels of IL-6 and the mentioned miRNAs. Methods: The study included 60 COVID-19 patients confirmed by an infectious disease specialist and positive real-time PCR tests, hospitalized at Razi Hospital, Ahvaz. The control group consisted of thirty healthy people. COVID-19 disease was verified using oro-nasopharyngeal swab samples, and PBMC samples from patients were used to check the expression level of IL-6. Plasma samples were analyzed for the expression levels of miR200b-3p, miR34b-5p, miR203a-3p, and Let7g-5p. Results: All examined expression factors were markedly elevated in COVID-19 patients in comparison to the control group. Specifically, miR200b-3p (P < 0.00), Let7g-5p (P < 0.003), and miR203a-3p (P < 0.00) exhibited significantly higher levels in the infected group. MiR34b-5p (P < 0.02) also showed an increase, albeit to a lesser extent. Additionally, IL-6 expression was substantially higher in hospitalized patients. Positive correlations, though not statistically significant, were observed between miR200b-5p, miR203a-3p, miR34b-5p, and IL-6 expression. Conversely, a non-significant negative correlation was noted between Let7g and IL-6 in COVID-19 patients. Conclusions: This study establishes a relationship between the elevated expression of specific miRNAs (miR200b-3p, miR34b-5p, miR203a-3p, and Let7g-5p) and IL-6 in COVID-19 patients. The significant upregulation of these miRNAs, alongside increased IL-6 levels, underscores their potential role as biomarkers for COVID-19. These findings suggest that miRNA and IL-6 expression profiles could be instrumental in the diagnosis and management of COVID-19, providing new avenues for therapeutic interventions and improving patient outcomes.
- 27 October 2020
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 19 (5) , 471-477
Prevalence of SARS-CoV-2 in Patients with Severe Pneumonia in Khuzestan Province, Iran
The emergence of a highly pathogenic virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accounts for severe pneumonia throughout the world. More than 7 million world population have been infected with SARS-CoV-2, and the number of deaths is increasing every day. This study aimed to evaluate the frequency of SARS-CoV-2 in hospitalized patients with acute respiratory infection (ARI). During an outbreak of the SARS-CoV-2, the nasopharyngeal and oropharyngeal swabs were collected from 909 hospitalized patients with severe pneumonia, including 517 (56.9%) males and 392 (43.1%) females. All the collected samples were from different cities of Khuzestan province from 19 February to- 27 March 2020. The RNA was extracted from samples and subjected to real-time polymerase chain reaction (PCR) tests for the detection of the SARS-CoV-2. Simultaneously, the computerized tomography (CT) scan was tested for the presence of ground-glass opacity in the lung among the patients. Of the total number of 909 specimens, 328 (36.08%) cases, including 185 (20.35%) females and 143 (15.73%) males, were positive for the SARS-CoV-2 while, 581 (63.9%) cases, including 374 (41.14%) males and 207 (22.77%) were negative for the SARS-CoV-2 by real-time PCR (p=0.001).Four hundred sixteen (45.76%) cases were positive for ground-glass opacity in the lung by CT scan, while 328/909 (36.08%) trials proved positive for SARS-CoV-2 by the real-time PCR (p=0.003). In this study, 36.08% of patients were positive for SARS-CoV-2. Although the results of positive cases by CT scan showed higher than real-time PCR, screening the SARS-CoV-2 with a real-time PCR method is the first line of choice.
- 27 October 2020
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 19 (5) , 471-477
Prevalence of SARS-CoV-2 in Patients with Severe Pneumonia in Khuzestan Province, Iran
The emergence of a highly pathogenic virus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accounts for severe pneumonia throughout the world. More than 7 million world population have been infected with SARS-CoV-2, and the number of deaths is increasing every day. This study aimed to evaluate the frequency of SARS-CoV-2 in hospitalized patients with acute respiratory infection (ARI). During an outbreak of the SARS-CoV-2, the nasopharyngeal and oropharyngeal swabs were collected from 909 hospitalized patients with severe pneumonia, including 517 (56.9%) males and 392 (43.1%) females. All the collected samples were from different cities of Khuzestan province from 19 February to- 27 March 2020. The RNA was extracted from samples and subjected to real-time polymerase chain reaction (PCR) tests for the detection of the SARS-CoV-2. Simultaneously, the computerized tomography (CT) scan was tested for the presence of ground-glass opacity in the lung among the patients. Of the total number of 909 specimens, 328 (36.08%) cases, including 185 (20.35%) females and 143 (15.73%) males, were positive for the SARS-CoV-2 while, 581 (63.9%) cases, including 374 (41.14%) males and 207 (22.77%) were negative for the SARS-CoV-2 by real-time PCR (p=0.001).Four hundred sixteen (45.76%) cases were positive for ground-glass opacity in the lung by CT scan, while 328/909 (36.08%) trials proved positive for SARS-CoV-2 by the real-time PCR (p=0.003). In this study, 36.08% of patients were positive for SARS-CoV-2. Although the results of positive cases by CT scan showed higher than real-time PCR, screening the SARS-CoV-2 with a real-time PCR method is the first line of choice.